The earnings beat was a combination of factors including slashing operating expenses and seeing big gains from key drugs like Cymbalta, which saw 22% growth for the quarter.
In this video, health care analyst David Williamson discusses the quarterly highlights, key takeaways for Eli Lilly investors, and important catalysts coming for the stock in the back half of 2013.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.